SNAPPS

Respiratory infections are considered the fifth “burden” to society measured by years lost through death or disability. Especially lower respiratory tract infections, caused by viruses and/or resistant bacteria strains, are a leading cause of death and disability. In Norway alone, 150 patients die each week from lung infections.

Unfortunately, current antimicrobial therapy often fails to reach deep into the lungs, where the core infectious sites are found. When the therapy does reach deep enough, the presence of superinfections involving antibiotic resistant bacteria still makes the infection challenging to combat.

Easing the burden on the health care system

In the project "Smart Nanotechnology for Pulmonary delivery of new generation antimicrobial Peptides to combat respiratory Superinfections" (SNAPPS) we will use advanced nanotechnology, in close collaboration with our industrial partners Pharma holdings and ACD Pharma, to deliver novel antimicrobials in a combined formulation of active drug substances to the lower respiratory tract for the first time.

Our goal is to develop a smart antimicrobial inhalation medicine that will make a difference on how we treat these infections. We aim to ease the burden on the health care system and hospitals, and ultimately to save patient lives.

Funding

SNAPPS is financed through the Norwegian Research Council (NRC).

Project period

2025-2028